Skip to main content

Table 4 Number of patients who completed treatment and reasons for discontinuation

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of patients (%)

 

DD/DI arm (N = 86)

HDI arm(N = 80)

Completed therapy

54

(63)

32

(40)

Reasons for discontinuation

    

Toxicity

11

(13)

14

(17)

Refusal

11

(13)

15

(19)

Disease Progression

10

(12)

19

(24)